Articles related to MULTIPLE SCLEROSIS (MS)

“Fenebrutinib represents the first potential scientific breakthrough for the PPMS community in over a decade.” — Levi Garraway, MD, PhD, Roche Chief Medical Officer

Patterns observed in pediatric-onset MS extend into young adult-onset disease, suggesting continuous rather than dichotomous age effects on health-related quality of life outcomes.

High-dose vitamin D demonstrated a 34% reduced risk of disease activity in both CIS and early RRMS patients, with MRI markers showing particular improvement, though no significant impact on clinical symptoms or disability progression was observed.

“The bottom line to me is that it is just further evidence that you really can modify immune phenotypes [characteristics] with dietary interventions.”

Early use of high-efficacy disease-modifying therapies in pediatric-onset MS patients with minimal disability reduces the risk of progression by 59% compared to no treatment.

A recent study involving 230 untreated relapsing-remitting MS patients found that vitamin D levels below 20 ng/mL were associated with a more than twofold increase in the risk of disease activity. This finding emphasizes the potential importance of vitamin D monitoring and management in MS patient care.